Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

@article{Schroeder2010ChangesIA,
  title={Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.},
  author={Fritz H. Schroeder and Bertrand F Tombal and Kurt Miller and Laurent Boccon-Gibod and Neal D Shore and E. David Crawford and Judd W. Moul and Tine Kold Olesen and B Persson},
  journal={BJU international},
  year={2010},
  volume={106 2},
  pages={182-7}
}
Study Type - Therapy (RCT) Level of Evidence 1b OBJECTIVE To compare the activity of degarelix, a new gonadotrophin-releasing hormone (GnRH) blocker, with leuprolide depot 7.5 mg in the control of total serum alkaline phosphatase (S-ALP) levels in patients with prostate cancer. PATIENTS AND METHODS In the randomized, phase III trial (CS21), patients with histologically confirmed prostate cancer (all stages), were randomized to one of three regimens: degarelix subcutaneous 240 mg for 1 month… CONTINUE READING